Right to Try Clarification Act

Bill 117 HR 8440, also known as the Right to Try Clarification Act, is a piece of legislation that aims to clarify and expand upon the existing Right to Try law. The Right to Try law was originally passed in 2018 and allows terminally ill patients to access experimental treatments that have not yet been fully approved by the Food and Drug Administration (FDA).

The Right to Try Clarification Act seeks to address some of the ambiguities and limitations of the original law. One key provision of the bill is to ensure that manufacturers of experimental treatments are protected from liability if a patient experiences adverse effects from the treatment. This provision is intended to encourage more manufacturers to make their experimental treatments available to patients under the Right to Try law.

Additionally, the bill clarifies that the FDA cannot use data from patients who access experimental treatments under the Right to Try law to delay or deny approval of the treatment. This provision is meant to ensure that patients who choose to access experimental treatments are not penalized for doing so. Overall, the Right to Try Clarification Act aims to strengthen and expand the existing Right to Try law, providing terminally ill patients with more options for accessing potentially life-saving treatments. The bill has received bipartisan support in Congress and is currently under consideration for passage.